EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 182 filers reported holding EAGLE PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is 2.65 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $214,000 | -42.6% | 4,809 | -36.2% | 0.00% | -33.3% |
| Q1 2022 | $373,000 | -3.4% | 7,543 | -0.5% | 0.01% | -14.3% |
| Q4 2021 | $386,000 | -11.3% | 7,581 | -2.7% | 0.01% | -22.2% |
| Q3 2021 | $435,000 | +61.7% | 7,791 | +24.0% | 0.01% | +80.0% |
| Q2 2021 | $269,000 | +691.2% | 6,282 | +681.3% | 0.01% | +400.0% |
| Q1 2021 | $34,000 | -91.2% | 804 | -91.2% | 0.00% | -91.7% |
| Q3 2020 | $388,000 | -11.6% | 9,119 | -0.1% | 0.01% | -14.3% |
| Q2 2020 | $439,000 | +4.3% | 9,130 | +0.1% | 0.01% | -6.7% |
| Q1 2020 | $421,000 | -24.4% | 9,119 | -1.9% | 0.02% | +25.0% |
| Q4 2019 | $557,000 | +992.2% | 9,295 | +635.4% | 0.01% | +1100.0% |
| Q4 2018 | $51,000 | -84.3% | 1,264 | -73.0% | 0.00% | -85.7% |
| Q3 2018 | $324,000 | -4.4% | 4,676 | +4.3% | 0.01% | 0.0% |
| Q2 2018 | $339,000 | +40.7% | 4,484 | -1.9% | 0.01% | +40.0% |
| Q1 2018 | $241,000 | +24000.0% | 4,571 | +28468.8% | 0.01% | – |
| Q4 2017 | $1,000 | – | 16 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Park West Asset Management LLC | 1,120,235 | $53,749,000 | 2.66% |
| TANG CAPITAL MANAGEMENT LLC | 255,616 | $12,264,000 | 1.19% |
| Smith, Graham & Co., Investment Advisors, LP | 158,671 | $7,613,000 | 0.92% |
| ARMISTICE CAPITAL, LLC | 282,000 | $13,530,000 | 0.59% |
| Capital Impact Advisors, LLC | 35,815 | $1,718,000 | 0.57% |
| Matarin Capital Management, LLC | 58,977 | $2,830,000 | 0.56% |
| GLOBEFLEX CAPITAL L P | 31,702 | $1,521,000 | 0.39% |
| CHARTWELL INVESTMENT PARTNERS, LLC | 200,246 | $9,608,000 | 0.37% |
| Stanley-Laman Group, Ltd. | 24,000 | $1,152,000 | 0.28% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 264 | $13,000 | 0.20% |